• Drug Education

    Oncology Drug Reference Sheet: Rucaparib

    Rucaparib (Rubraca®) has U.S. Food and Drug Administration (FDA) approval for both maintenance and treatment indications in gynecologic cancers. It originally received accelerated approval in 2016 for the treatment of deleterious, BRCA variant–associated advanced ovarian cancer that has failed two or more chemotherapies. In 2018, it was approved for maintenance therapy of various gynecologic malignancies. Most recently, rucaparib received approval for BRCA-positive metastatic castration-resistant prostate cancer treatment after androgen-directed and chemotherapy.
  • Blog

    Members Save Hundreds on ONS Congress® Registration—and the Benefits Continue Even After the Conference

    ONS offers oncology nurses a multitude of benefits through membership, including the opportunity to save hundreds on registration for the 47th Annual ONS Congress and access on-demand content following the conference.  
  • Voice Articles

    APRNs Collaborate With PCPs on Shared Survivorship Care Models

    Although they’ve conquered cancer, survivors may develop late or long-term physical, psychosocial, practical, or spiritual effects from the disease or its treatment. For example, patients with breast cancer who have completed surgery, radiation, or chemotherapy should be monitored for recurrence, lymphedema, osteoporosis, and cardiac, hormone-related, and sexual issues.
  • Voice Articles

    Palliative Care Resources Comfort Nurses Through COVID-19 Stress, Dilemmas, and Grief

    The concept of providing comfort is at the core of my identity as a nurse, and I have always been drawn to the palliative care component of what we do as oncology nurses. Because it wasn’t part of my roles, I was less confident in my knowledge and understanding of chemotherapy administration, but I often thought, “Palliative care, yeah, I’ve got this!”

    And then I learned how little I knew.
  • Voice Articles

    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer

    Clinical trial results show that PD-1 inhibitors offer improved survival and a better safety profile compared to standard, single-agent chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. However, because of their mechanism of action as immunotherapy, patients receiving the agents may experience immune-related adverse events (irAEs).
  • Drug Education

    Oncology Drug Reference Sheet: Trilaciclib

    On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (CoselaTM), a parenteral inhibitor of cyclin-dependent kinase (CDK), to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.
  • Voice Articles

    Oncology Drug Reference Sheet: Fruquintinib

    In two clinical trials, patients who received fruquintinib (Fruzaqla™) had an overall survival of 7.4 and 9.3 months compared to 4.8 and 6.6 months with placebo, leading to the drug’s November 2023 U.S. Food and Drug Administration approval for adults with metastatic colorectal cancer who previously received standard chemotherapy and experienced disease progression. 

  • Voice Articles

    PARP Inhibitors and Ovarian Cancer

    Before poly (adenosine diphosphate-ribose) polymerase inhibitors were approved for ovarian cancer, traditional treatment consisted of surgical cytoreduction and platinum-based chemotherapy with a taxane, with or without bevacizumab, depending on stage and type. With the surgery-chemotherapy combination, 70%–75% of patients had recurrence and overall five-year survival rate were 29%, indicating a need for additional therapies.